Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Liang, Y. [1 ]
Krupsky, K. [2 ]
Lankin, J. [2 ]
Cohn, J. [2 ]
Kashine, N. [2 ]
Honomichl, R. [2 ]
Rattigan-Brown, Y. [1 ]
Shehu, A. [1 ]
Salomonsen, R. [1 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] Oracle Life Sci, Austin, TX USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
early-stage NSCLC; osimertinib; physician preferences;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP.07E.02
引用
收藏
页码：S553 / S553
页数：1
相关论文
共 50 条
  • [41] Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients
    Oka, T.
    Kamada, R.
    Kunimasa, K.
    Oboshi, M.
    Nishikawa, T.
    Yasui, T.
    Shioyama, W.
    Miyashita, Y.
    Koyama, T.
    Kumagai, T.
    Fujita, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 881 - 881
  • [42] Survival mechanisms of osimertinib-tolerant persister cells in EGFR-mutated non-small cell lung cancer
    Haga, Yuya
    Nishimura, Akihide
    Higashisaka, Kazuma
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2025, 116 : 1551 - 1551
  • [43] Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
    Zeng, Beilei
    Gan, Kelun
    Yu, Yuanhang
    Hu, Jianping
    Deng, Qiao
    Yin, Chong
    Gao, Xi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiotherapy
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y. C.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E380 - E381
  • [45] Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Kim, H.
    Han, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1120
  • [46] Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery
    Zhang, Q.
    Ke, L.
    Xu, J.
    He, C.
    He, T.
    Zhou, Z.
    Lv, W.
    Hu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1550 - S1550
  • [47] EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Setinek, Ulrike
    Pirker, Robert
    Filipits, Martin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 239 - +
  • [48] Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer
    Kim, Edward S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 370
  • [49] Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer
    Hori, Tomoki
    Yamamoto, Kazuhiro
    Ito, Takefumi
    Ikushima, Shigeki
    Omura, Tomohiro
    Yano, Ikuko
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (03) : 281 - 288
  • [50] Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
    Mambetsariev, Isa
    Arvanitis, Leonidas
    Fricke, Jeremy
    Pharaon, Rebecca
    Baroz, Angel R.
    Afkhami, Michelle
    Koczywas, Marianna
    Massarelli, Erminia
    Salgia, Ravi
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (05)
12345